Delivering non-toxic drugs to the brain for Alzheimer's treatment
Official title: Non-toxic CNS drug delivery across the BBB in Alzheimer's and other dementias
Funded at Somatoceutics, LLC · NIH-10920948 · Data updated 2026-11-12
This study is exploring a new way to help deliver medications to the brain for people with Alzheimer's and similar conditions, using tiny technology to make treatments safer and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Somatoceutics, LLC NIH-funded |
| Lab location | 1 site (Mt Pleasant, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $474,531 |
| NIH project number | 1R41AG079748-01A1 |
| Project ID | NIH-10920948 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias.
✕Less likely to help
Patients with other forms of dementia not related to Alzheimer's may not benefit from this research.
What this research studies
This research focuses on developing a new method to deliver drugs across the blood-brain barrier (BBB) specifically for Alzheimer's disease and related dementias. The approach utilizes innovative nanotechnology, including peptide-based nanotubes, to encapsulate drugs and minimize their toxicity. By overcoming the challenges of traditional drug delivery methods, this research aims to create safer and more effective treatments for patients suffering from these conditions. The project is led by Somatoceutics, LLC, and aims to provide new diagnostic and therapeutic tools.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for Alzheimer's disease and related dementias.
How similar studies have gone: While there have been various attempts to use nanotechnology for drug delivery in neurological conditions, this specific approach using peptide-based nanotubes is relatively novel.
Where this research is happening
-
Somatoceutics, LLC
Mt Pleasant, United States Active
Researchers
- Principal investigator: Rosenzweig, Steven Alan — Somatoceutics, LLC
- Study coordinator: Rosenzweig, Steven Alan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.